Analyst Expectations for Rain Oncology's Future
Portfolio Pulse from Benzinga Insights
In the last quarter, Rain Oncology (NASDAQ:RAIN) received 4 bullish, 1 somewhat bullish, and 3 indifferent analyst ratings. The company has an average 12-month price target of $10.91, representing a 35.82% decrease from the previous average of $17.00.
May 23, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rain Oncology received mixed analyst ratings in the last quarter, with an average 12-month price target of $10.91, down 35.82% from the previous average.
The mixed analyst ratings for Rain Oncology indicate uncertainty in the stock's short-term performance. The decrease in the average 12-month price target suggests a potential downside, but the presence of bullish ratings also indicates some positive sentiment. This leads to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100